J.Jpn. Surg. Soc.. 79(8): 823-827, 1978
Report on the annual meeting
SURGERY FOR LUNG CANCER AND ADJUVANT IMMUNOTHERAPY
|
Department of Chest Surgery, Kyushu Cancer Center Mitsuo Ohta |
Prolongation of survival periods was revealed after BCG-CWS treatment in each clinical stage of lung cancer. In resected cases the survival rate of control patients and BCG-CWS treated patients were 28% and 61% respectively at 36 months (p value＜0.001).
In vitro lymphocyte responses which were assessed later than 4 months after the start of BCG-CWS treatment correlated well with the prognosis of patients.
Pathological examination of autopsied cases suggested that BCG-CWS treatment not only suppresses hematogenous metastases but also augments resistance against microorganisms.
Immunotherapy would seem to be most appropriate as an adjuvant modality following resectional surgery for lung cancer.
To read the PDF file you will need Adobe Reader installed on your computer.